[go: up one dir, main page]

CY1121350T1 - Απο του στοματος φαρμακοτεχνικες μορφες αναλογων κυτιδινης και μεθοδοι χρησης αυτων - Google Patents

Απο του στοματος φαρμακοτεχνικες μορφες αναλογων κυτιδινης και μεθοδοι χρησης αυτων

Info

Publication number
CY1121350T1
CY1121350T1 CY20191100231T CY191100231T CY1121350T1 CY 1121350 T1 CY1121350 T1 CY 1121350T1 CY 20191100231 T CY20191100231 T CY 20191100231T CY 191100231 T CY191100231 T CY 191100231T CY 1121350 T1 CY1121350 T1 CY 1121350T1
Authority
CY
Cyprus
Prior art keywords
methods
oral pharmaceutical
pharmaceutical forms
cytidine analogs
cytidine
Prior art date
Application number
CY20191100231T
Other languages
English (en)
Inventor
Jeffrey B. Etter
Mei Lai
Jay Thomas Backstrom
Original Assignee
Celgene Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40941609&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1121350(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celgene Corporation filed Critical Celgene Corporation
Publication of CY1121350T1 publication Critical patent/CY1121350T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα αποκάλυψη παρέχει φαρμακευτικές συνθέσεις που περιλαμβάνουν ανάλογα κυτιδίνης για από του στόματος χορήγηση, όπου οι συνθέσεις απελευθερώνουν το ανάλογο κυτιδίνης ουσιαστικά στο στομάχι. Επίσης παρέχονται μέθοδοι θεραπείας ασθενειών και διαταραχών που χρησιμοποιούν τις από του στόματος φαρμακοτεχνικές μορφές που παρέχονται στο παρόν.
CY20191100231T 2008-05-15 2019-02-25 Απο του στοματος φαρμακοτεχνικες μορφες αναλογων κυτιδινης και μεθοδοι χρησης αυτων CY1121350T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5360908P 2008-05-15 2008-05-15
US20114508P 2008-12-05 2008-12-05
US15787509P 2009-03-05 2009-03-05
PCT/US2009/002999 WO2009139888A1 (en) 2008-05-15 2009-05-14 Oral formulations of cytidine analogs and methods of use thereof

Publications (1)

Publication Number Publication Date
CY1121350T1 true CY1121350T1 (el) 2020-05-29

Family

ID=40941609

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20191100231T CY1121350T1 (el) 2008-05-15 2019-02-25 Απο του στοματος φαρμακοτεχνικες μορφες αναλογων κυτιδινης και μεθοδοι χρησης αυτων
CY20201100168T CY1122681T1 (el) 2008-05-15 2020-02-24 Απο του στοματος σκευασματα αναλογων κυτιδινης και μεθοδοι χρησης αυτων
CY20211100917T CY1124720T1 (el) 2008-05-15 2021-10-20 Απο του στοματος σκευασματα αναλογων κυτιδινης και μεθοδοι χρησης αυτων

Family Applications After (2)

Application Number Title Priority Date Filing Date
CY20201100168T CY1122681T1 (el) 2008-05-15 2020-02-24 Απο του στοματος σκευασματα αναλογων κυτιδινης και μεθοδοι χρησης αυτων
CY20211100917T CY1124720T1 (el) 2008-05-15 2021-10-20 Απο του στοματος σκευασματα αναλογων κυτιδινης και μεθοδοι χρησης αυτων

Country Status (34)

Country Link
US (12) US8846628B2 (el)
EP (6) EP3782611B1 (el)
JP (3) JP2011520880A (el)
KR (1) KR101633134B1 (el)
CN (3) CN102099018B (el)
AR (1) AR071808A1 (el)
AU (3) AU2009246926B2 (el)
BR (1) BRPI0912717A2 (el)
CA (3) CA3094590A1 (el)
CL (2) CL2009001170A1 (el)
CO (1) CO6300930A2 (el)
CR (1) CR11789A (el)
CY (3) CY1121350T1 (el)
DK (5) DK2299984T3 (el)
EC (1) ECSP10010665A (el)
ES (5) ES2774226T3 (el)
FI (1) FI3782612T3 (el)
HR (5) HRP20190100T1 (el)
HU (5) HUE042825T2 (el)
IL (2) IL238087B (el)
LT (5) LT3782611T (el)
MX (2) MX2010012470A (el)
MY (1) MY161593A (el)
NI (1) NI201000193A (el)
NZ (3) NZ589437A (el)
PE (2) PE20091971A1 (el)
PL (5) PL3692983T3 (el)
PT (5) PT3782612T (el)
RU (3) RU2476207C2 (el)
SG (1) SG193206A1 (el)
SI (5) SI3692983T1 (el)
TW (3) TWI618538B (el)
WO (1) WO2009139888A1 (el)
ZA (1) ZA201008229B (el)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8404716B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404717B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes using lenalidomide
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US6943249B2 (en) * 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US8497292B2 (en) * 2005-12-28 2013-07-30 Translational Therapeutics, Inc. Translational dysfunction based therapeutics
CA2742252A1 (en) * 2007-11-01 2009-05-07 Celgene Corporation Cytidine analogs for treatment of myelodysplastic syndromes
US20150290228A1 (en) * 2008-05-15 2015-10-15 Jay T. BACKSTROM Oral formulations of cytidine analogs and methods of use thereof
AU2009246926B2 (en) 2008-05-15 2014-06-26 Celgene Corporation Oral formulations of cytidine analogs and methods of use thereof
WO2010093435A1 (en) * 2009-02-10 2010-08-19 Celgene International Sarl Methods for treating non-small cell lung cancer using 5-azacytidine
US8491927B2 (en) 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
US20110301102A1 (en) * 2010-06-07 2011-12-08 Telik, Inc. Compositions and methods for treating myelodysplastic syndrome
US8759303B2 (en) 2010-06-07 2014-06-24 Telik, Inc. Compositions and methods for treating myelodysplastic syndrome
MY166014A (en) * 2010-06-07 2018-05-21 Abraxis Bioscience Llc Combination therapy methods for treating proliferative diseases
CN103338753A (zh) 2011-01-31 2013-10-02 细胞基因公司 胞苷类似物的药物组合物及其使用方法
EP2481813A1 (en) * 2011-02-01 2012-08-01 Centro di Riferimento Oncologico - Istituto Nazionale Tumori - Aviano Markers of cutaneous melanoma and uses thereof
JP6289361B2 (ja) 2011-03-31 2018-03-07 セルジーン インターナショナル サルル ５−アザシチジンの合成
HK1200716A1 (zh) 2011-11-01 2015-08-14 细胞基因公司 使用胞苷類似物的口服製劑治療癌症的方法
MY176125A (en) 2011-11-03 2020-07-24 Takeda Pharmaceuticals Co Administration of nedd8-activating enzyme inhibitor and hypomethylating agent
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
MX2015000804A (es) * 2012-07-20 2016-03-11 Star Biotechnology Llc Composiciones y metodos para tratar el sarcoma de ewing y otros trastornos relacionados con ews-fli1.
JP6444883B2 (ja) * 2012-11-29 2018-12-26 タカラ バイオ ヨーロッパ アーベー 哺乳類多能性幹細胞由来の内胚葉細胞を産生するための改良された方法
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
EA036325B1 (ru) 2014-03-14 2020-10-27 Аджиос Фармасьютикалз, Инк. Фармацевтическая композиция на основе твердой дисперсии ингибитора idh1
WO2015195634A1 (en) 2014-06-17 2015-12-23 Celgne Corporation Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
EP3925609B1 (en) 2014-08-22 2025-07-30 Celgene Corporation Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
JP2018515566A (ja) * 2015-05-22 2018-06-14 ノバルティス アーゲー 医薬組成物
UA123401C2 (uk) 2015-10-15 2021-03-31 Аджиос Фармасьютікалз, Інк. Комбінована терапія для лікування злоякісних пухлин
CA3002029A1 (en) * 2015-10-15 2017-04-20 Celgene Corporation Combination therapy for treating malignancies
ES2897959T3 (es) * 2015-10-15 2022-03-03 Servier Lab Terapia de combinación para tratar neoplasias malignas
DK3960182T3 (da) 2015-12-03 2025-04-07 Epidestiny Inc Sammensætninger indeholdende decitabin, 5-azacytidin og tetrahydrouridin samt anvendelser deraf
US11035850B2 (en) 2016-04-12 2021-06-15 The Johns Hopkins University Quantitative determination of nucleoside analogue drugs in genomic DNA or RNA
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
EA039874B1 (ru) * 2019-06-06 2022-03-22 Общество С Ограниченной Ответственностью "Технология Лекарств" Композиция помалидомида для лечения заболеваний, ассоциированных с фактором некроза опухоли (фно)
BR112021025537A2 (pt) 2019-06-20 2022-03-03 Celgene Quanticel Res Inc Azacitidina em combinação com venetoclax, gilteritinibe, midostaurina ou outros compostos para o tratamento de leucemia ou síndrome mielodisplásica
JP7680762B2 (ja) * 2019-09-25 2025-05-21 アードバーク・セラピューティクス・インコーポレイテッド 経口速放出性医薬組成物および減量治療の方法
TW202128191A (zh) 2019-10-21 2021-08-01 瑞士商諾華公司 Tim-3抑制劑及其用途
MX2022004766A (es) 2019-10-21 2022-05-16 Novartis Ag Terapias combinadas con venetoclax e inhibidores de tim-3.
JP7653712B2 (ja) * 2019-12-18 2025-03-31 一般社団法人東京血液疾患研究所 高リスク骨髄異形成症候群の治療薬
TW202135859A (zh) 2019-12-20 2021-10-01 瑞士商諾華公司 組合療法
EP4085902B1 (en) * 2019-12-31 2025-04-30 Jiangsu Yahong Meditech Co., Ltd. Pharmaceutical composition containing nitroxoline, nitroxoline tablet, preparation method therefor and use thereof
BR112022012310A2 (pt) 2020-01-17 2022-09-06 Novartis Ag Combinação compreendendo um inibidor de tim-3 e um agente hipometilante para uso no tratamento de síndrome mielodisplásica ou leucemia mielomonocítica crônica
CN115768432A (zh) 2020-04-23 2023-03-07 南方研究院 使用4’-硫代-5-氮杂-2’-脱氧胞苷来治疗血癌的组合物及其用途
CA3186696A1 (en) 2020-07-23 2022-01-27 Mark J. Suto Polymorphs of 5-aza-4'-thio-2-deoxycytidine
AU2021386422A1 (en) * 2020-11-27 2023-07-06 Centre Leon Berard Ribosomal rnas 2'o-methylation as a novel source of biomarkers relevant for diagnosis, prognosis and therapy of cancers
US11858956B2 (en) 2020-12-18 2024-01-02 Southern Research Institute 6-aza-nucleoside prodrugs as antiviral agents for treating virus infections
WO2022192621A1 (en) 2021-03-12 2022-09-15 Celgene Corporation Methods for using a hypomethylating agent to treat diseases and disorders based on gene mutation profiles
AU2022370354A1 (en) 2021-10-19 2024-05-30 Akirabio, Inc. Compositions comprising 2'-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers
US20250195653A1 (en) 2023-11-28 2025-06-19 Sanofi Multifunctional natural killer (nk) cell engager combination therapy for treating hematological neoplastic disorders
CN118903036B (zh) * 2024-10-10 2025-03-04 华夏罕见病药物研发(山东)有限公司 一种含尿苷的组合物的制备方法及其在治疗发育性癫痫性脑病50型中的应用

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2913408A (en) 1956-12-28 1959-11-17 Dow Chemical Co Corrosion inhibitors for ferrous metals in aqueous solutions of non-oxidizing acids
GB1050899A (el) 1963-12-22
CH527207A (de) 1968-05-08 1972-08-31 Ceskoslovenska Akademie Ved Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
CH507969A (de) 1968-11-12 1971-05-31 Ceskoslovenska Akademie Ved Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
DE2012888C3 (de) 1970-03-14 1981-04-02 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von 5-Azapyrimidinnucleosiden
FR2123632A6 (en) 1971-01-26 1972-09-15 Ceskoslovenska Akademie Ved Prepn of 5-azacytosines and 5-azacytidines - from bis trimethylsilyl-5-azacytosine
DE2122991C2 (de) 1971-05-04 1982-06-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von Cytosin- und 6-Azacytosinnucleosiden
DE2508312A1 (de) 1975-02-24 1976-09-02 Schering Ag Neues verfahren zur herstellung von nucleosiden
DE2757365A1 (de) 1977-12-20 1979-06-21 Schering Ag Neues verfahren zur herstellung von nucleosiden
JPS59151784U (ja) 1983-03-30 1984-10-11 日産自動車株式会社 トラツクのリヤボデイ構造
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
EP0397042B1 (de) 1989-05-10 1995-08-16 F. Hoffmann-La Roche Ag Herstellung von Isochinolinderivaten
US5360352A (en) 1992-12-24 1994-11-01 The Whitaker Corporation Wire retainer for current mode coupler
US6432924B1 (en) 1993-12-26 2002-08-13 East Carolina University Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase
GB9412394D0 (en) 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
US5700640A (en) 1994-09-16 1997-12-23 Basf Aktiengesellschaft Inducers of gamma globin gene expression and screening assays therefor
US5539209A (en) 1994-10-17 1996-07-23 Trojan Technologies Inc. Method of cleaning fouling materials from a radiation module
AU738170B2 (en) 1996-10-16 2001-09-13 Icn Pharmaceuticals, Inc. Monocyclic L-nucleosides, analogs and uses thereof
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
PT998271E (pt) 1997-06-06 2005-10-31 Depomed Inc Formas de dosagem oral de farmacos com retencao gastrica para a libertacao controlada de farmacos altamente soluveis
US6200604B1 (en) 1998-03-27 2001-03-13 Cima Labs Inc. Sublingual buccal effervescent
US6566395B1 (en) 1999-05-25 2003-05-20 Biomedicines, Inc. Methods of treating proliferative disorders
US6803195B1 (en) 1999-07-02 2004-10-12 Ramot At Tel-Aviv University Ltd. Facile detection of cancer and cancer risk based on level of coordination between alleles
KR20020012006A (ko) 1999-07-16 2002-02-09 오오쯔끼쥰조 점막 흡수용 글리시리진 제제
US20030180352A1 (en) 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
PT1251832E (pt) 2000-02-04 2007-01-31 Depomed Inc Forma de dosagem constituída por invólucro-e-núcleo que conduz a uma libertação do fármaco de ordem zero
GB0102342D0 (en) 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
WO2002098420A1 (en) 2001-06-01 2002-12-12 Cytovia, Inc. 4-substituted-1-(arylmethylidene)thiosemicarbazide, 4-substituted-1-(arylcarbonyl)thiosemicarbazide and analogs as activators of caspases and inducers of apoptosis and the use thereof
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US20030220254A1 (en) 2002-03-29 2003-11-27 Texas Tech University System Composition and method for preparation of an oral dual controlled release formulation of a protein and inhibitor
US7772197B2 (en) 2002-09-24 2010-08-10 1,3,5-Triazines for Treatment of Viral Diseases 1,3,5-triazines for treatment of viral diseases
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
EP1556010A4 (en) 2002-10-31 2007-12-05 Supergen Inc PHARMACEUTICAL FORMULATIONS; WHICH ARE ADDRESSED TO CERTAIN REGIONS OF THE STOMACH-DARM TRAKTS
EP1581213A4 (en) 2002-12-18 2008-11-19 Cytovia Inc 3,5-DISUBSTITUTED 1,2,4-OXADIAZOLE AND ANALOGUE TO ACTIVATE CASPASE AND INTRODUCTION OF APOPTOSIS AND THEIR USE
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US7038038B2 (en) 2003-03-17 2006-05-02 Pharmion Corporation Synthesis of 5-azacytidine
AU2004241729A1 (en) 2003-05-21 2004-12-02 Novartis Ag Combination of histone deacetylase inhibitors with chemotherapeutic agents
JP2007504131A (ja) * 2003-08-29 2007-03-01 エートン ファーマ インコーポレーティッド 癌の組み合わせ処置法
US7192781B2 (en) 2004-04-13 2007-03-20 Pharmion Corporation Methods for stabilizing 5-azacytidine in plasma
US20060069060A1 (en) 2004-09-27 2006-03-30 Sanjeev Redkar Salts of decitabine
US20060063735A1 (en) 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
CN100374160C (zh) * 2004-11-22 2008-03-12 山东蓝金生物工程有限公司 一种含抗代谢类药物的抗癌药物组合物
US20060128654A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
CA2598239C (en) 2005-02-18 2019-10-29 Abraxis Bioscience, Inc. Nanoparticulate formulations of taxanes and carrier proteins for use in combination chemotherapy
NZ561178A (en) 2005-03-07 2010-11-26 Bayer Schering Pharma Ag Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
CN100500212C (zh) * 2005-04-06 2009-06-17 山东蓝金生物工程有限公司 一种抗实体肿瘤药物组合物
US8058260B2 (en) 2006-05-22 2011-11-15 Xenoport, Inc. 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof
WO2008028193A2 (en) 2006-09-01 2008-03-06 Pharmion Corporation Colon-targeted oral formulations of cytidine analogs
US7759481B2 (en) 2007-01-11 2010-07-20 Ivax Corporation Solid state forms of 5-azacytidine and processes for preparation thereof
WO2008092127A1 (en) 2007-01-25 2008-07-31 Nevada Cancer Institute Use of acetylated or esterificated azacytidine, decitabine, or other nucleoside analogs as oral agents for the treatment of tumors or other dysplastic syndromes sensitive to hypomethylating agents
JP5173298B2 (ja) 2007-07-25 2013-04-03 キヤノン株式会社 プリント配線板およびそれを用いた電子機器
EP2176279A4 (en) 2007-08-02 2012-01-11 Chemagis Ltd HIGH-PURITY, STABLE AZACYTIDINE AND METHODS OF PREPARATION
US8399420B2 (en) 2007-09-26 2013-03-19 Mount Sanai School of Medicine Azacytidine analogues and uses thereof
EP2048151A1 (en) 2007-10-10 2009-04-15 Cilag AG Method for producing nucleosides by direct glycosylation of the nucleoside base
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
CA2742252A1 (en) 2007-11-01 2009-05-07 Celgene Corporation Cytidine analogs for treatment of myelodysplastic syndromes
AU2009246926B2 (en) * 2008-05-15 2014-06-26 Celgene Corporation Oral formulations of cytidine analogs and methods of use thereof
EP2321302B1 (en) 2008-08-01 2014-10-29 Dr. Reddy's Laboratories Ltd. Azacitidine process and polymorphs
WO2010017374A1 (en) 2008-08-06 2010-02-11 Sicor Inc. Process for preparing azacytidine intermediate
KR101660549B1 (ko) 2008-08-08 2016-09-27 시노팜 타이완 리미티드 ５―아자시토신 뉴클레오시드 및 이의 유도체의 제조 방법
KR20170015525A (ko) 2008-11-22 2017-02-08 제넨테크, 인크. 유방암의 치료를 위한, 화학요법과 조합된 항-ｖｅｇｆ 항체의 용도
US20110042247A1 (en) 2009-06-25 2011-02-24 Chandrasekhar Kocherlakota Formulations of azacitidine and its derivatives
WO2011014541A1 (en) 2009-07-30 2011-02-03 Eagle Pharmaceuticals, Inc. Stable formulations of azacitidine
IT1399195B1 (it) 2010-03-30 2013-04-11 Chemi Spa Processo per la sintesi di azacitidina e decitabina
CN103338753A (zh) 2011-01-31 2013-10-02 细胞基因公司 胞苷类似物的药物组合物及其使用方法
JP6289361B2 (ja) 2011-03-31 2018-03-07 セルジーン インターナショナル サルル ５−アザシチジンの合成
WO2013022872A1 (en) 2011-08-10 2013-02-14 Celgene Corporation Gene methylation biomarkers and methods of use thereof
HK1200716A1 (zh) 2011-11-01 2015-08-14 细胞基因公司 使用胞苷類似物的口服製劑治療癌症的方法

Also Published As

Publication number Publication date
HRP20200096T1 (hr) 2020-04-03
CY1124720T1 (el) 2022-07-22
LT2695609T (lt) 2020-02-10
US20230241086A1 (en) 2023-08-03
JP2017137326A (ja) 2017-08-10
PT2695609T (pt) 2020-03-02
US20180153916A1 (en) 2018-06-07
PL3782611T3 (pl) 2022-11-07
PT3782612T (pt) 2024-01-18
AU2013202665B2 (en) 2015-06-25
EP3692983B1 (en) 2021-08-11
FI3782612T3 (fi) 2024-01-16
BRPI0912717A2 (pt) 2014-12-23
EP3782612A1 (en) 2021-02-24
DK2695609T3 (da) 2020-02-10
NZ602833A (en) 2014-04-30
RU2012147739A (ru) 2014-05-20
US20230255996A1 (en) 2023-08-17
HUE047707T2 (hu) 2020-05-28
EP3782611A1 (en) 2021-02-24
SI2299984T1 (sl) 2019-04-30
PT3692983T (pt) 2021-11-08
HRP20190100T1 (hr) 2019-04-05
LT3782612T (lt) 2023-12-27
US20150056280A1 (en) 2015-02-26
US20220079964A1 (en) 2022-03-17
JP2015110575A (ja) 2015-06-18
AU2015202884A1 (en) 2015-06-18
CL2013001097A1 (es) 2013-11-29
IL238087B (en) 2019-01-31
CY1122681T1 (el) 2020-10-14
EP3782612B1 (en) 2023-11-08
CA2761582C (en) 2022-06-07
US12053482B2 (en) 2024-08-06
JP6426778B2 (ja) 2018-11-21
TWI618538B (zh) 2018-03-21
HUE064677T2 (hu) 2024-04-28
ECSP10010665A (es) 2011-01-31
ES2774226T3 (es) 2020-07-17
EP2299984A1 (en) 2011-03-30
TW201006478A (en) 2010-02-16
DK2299984T3 (en) 2019-03-04
US20200101095A1 (en) 2020-04-02
CO6300930A2 (es) 2011-07-21
SI3692983T1 (sl) 2021-11-30
PT3782611T (pt) 2022-11-18
RU2476207C2 (ru) 2013-02-27
AU2009246926A1 (en) 2009-11-19
US20200316099A1 (en) 2020-10-08
US10646503B2 (en) 2020-05-12
NZ589437A (en) 2012-11-30
ES2969144T3 (es) 2024-05-16
EP3782611B1 (en) 2022-07-06
US10463683B2 (en) 2019-11-05
LT3782611T (lt) 2022-10-10
PE20091971A1 (es) 2010-01-15
US20190231803A1 (en) 2019-08-01
ES2712506T3 (es) 2019-05-13
PT2299984T (pt) 2019-02-25
TW201729817A (zh) 2017-09-01
CL2009001170A1 (es) 2010-06-04
TW201513869A (zh) 2015-04-16
EP2695609B1 (en) 2019-12-11
LT2299984T (lt) 2019-03-25
KR101633134B1 (ko) 2016-06-23
PL3692983T3 (pl) 2021-12-27
CN102099018B (zh) 2016-01-13
AU2009246926B2 (en) 2014-06-26
NI201000193A (es) 2011-08-01
EP3692983A1 (en) 2020-08-12
US20150374732A1 (en) 2015-12-31
RU2018109222A3 (el) 2021-07-02
SI3782611T1 (sl) 2022-10-28
US10220050B2 (en) 2019-03-05
HUE042825T2 (hu) 2019-07-29
CA3094580A1 (en) 2009-11-19
RU2018109222A (ru) 2019-09-17
LT3692983T (lt) 2021-11-10
NZ623495A (en) 2015-08-28
US20090286752A1 (en) 2009-11-19
IL209307A0 (en) 2011-01-31
MX2010012470A (es) 2010-12-02
HRP20231439T1 (hr) 2024-03-01
ES2893785T3 (es) 2022-02-10
EP2695609A1 (en) 2014-02-12
MY161593A (en) 2017-04-28
AR071808A1 (es) 2010-07-14
US11571436B2 (en) 2023-02-07
WO2009139888A1 (en) 2009-11-19
DK3782611T3 (da) 2022-09-05
PE20142440A1 (es) 2015-01-28
CN105535008A (zh) 2016-05-04
AU2015202884B2 (en) 2017-02-23
HUE059635T2 (hu) 2022-12-28
HUE055911T2 (hu) 2021-12-28
SI3782612T1 (sl) 2024-02-29
CA2761582A1 (en) 2009-11-19
EP2299984B1 (en) 2018-11-28
EP4327888A3 (en) 2024-05-22
PL2299984T3 (pl) 2019-07-31
ES2927556T3 (es) 2022-11-08
HRP20211398T1 (hr) 2021-12-10
MX363023B (es) 2019-03-05
HRP20221064T1 (hr) 2022-11-11
TWI522103B (zh) 2016-02-21
AU2013202665A1 (en) 2013-05-02
US20250082661A1 (en) 2025-03-13
IL209307A (en) 2016-02-29
PL2695609T3 (pl) 2020-05-18
US8846628B2 (en) 2014-09-30
CN103479586B (zh) 2017-03-01
US20220105118A1 (en) 2022-04-07
DK3782612T3 (da) 2024-01-15
PL3782612T3 (pl) 2024-03-04
SG193206A1 (en) 2013-09-30
DK3692983T3 (da) 2021-09-20
SI2695609T1 (sl) 2020-03-31
JP2011520880A (ja) 2011-07-21
CN103479586A (zh) 2014-01-01
EP4327888A2 (en) 2024-02-28
CN102099018A (zh) 2011-06-15
JP6105547B2 (ja) 2017-03-29
CR11789A (es) 2011-02-21
ZA201008229B (en) 2012-02-29
CA3094580C (en) 2021-05-18
CA3094590A1 (en) 2009-11-19
RU2010151428A (ru) 2012-06-20
KR20110015629A (ko) 2011-02-16
RU2765076C2 (ru) 2022-01-25

Similar Documents

Publication Publication Date Title
CY1121350T1 (el) Απο του στοματος φαρμακοτεχνικες μορφες αναλογων κυτιδινης και μεθοδοι χρησης αυτων
CY1121593T1 (el) Προφαρμακα της τετραϋδροκανναβινολης, συνθεσεις οι οποιες περιλαμβανουν προφαρμακα της τετραϋδροκανναβινολης και μεθοδοι χρησης των ιδιων
CY1123050T1 (el) Φαρμακα ινδολιδονης για την θεραπεια ή προληψη ινωτικων ασθενειων
CY1118956T1 (el) Νεες θεραπευτικες προσεγγισεις για τη θεραπευτικη αντιμετωπιση της νοσου alzheimer και των συγγενων διαταραχων μεσω διαμορφωσης της αγγειογενεσης
MX392606B (es) Composiciones para la liberacion controlada de cisteamina y el tratamiento sistemico de trastornos sensibles a la cisteamina.
CY1118017T1 (el) Υποβαλλοντας σε αγωγη την ανεπαρκεια και το ελλειμμα βιταμινης d με 25-υδροξυβιταμινη d2 και 25-υδροξυβιταμινη d3
CY1118731T1 (el) Φαρμακευτικες συνθεσεις αλβιγλουτιδης
CY1117237T1 (el) Συνθεσεις σταθερων τιακουμυκινων
CY1118179T1 (el) Φαρμακευτικη συνθεση
CY1110824T1 (el) Διασπεipoμενη στο στομα φαρμακευτικη συνθεση για απο του στοματος, μεσω του στοματικου βλεννογονου ή υπογλωσσια χορηγηση αγομελατινης
CY1117995T1 (el) Δευτεριωμενα παραγωγα κατεχολαμινης και φαρμακα που περιεχουν τις εν λογω ενωσεις
CY1117584T1 (el) Παραγωγα 1-βενζυλ-3-υδροξυμεθυλινδαζολης και η χρηση τους στη θεραπευτικη αντιμετωπιση νοσων που βασιζονται στην εκφραση των mcp-1, cx3cr1
NO20076508L (no) Acyloksykarbamat prodroger av traneksaminsyre og fremgangsmater for fremstilling og anvendelse derav
CY1111977T1 (el) Παραγωγα πιπεριδιν-4-υλ-πυριδαζιν-3-υλαμινης ως ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2
GT200500325A (es) Pirazolo-pirimidinas 1,4-sustituidas como inhibidores de quinasa
CY1107894T1 (el) Προφαρμακα αναλογων gaba, συνθεσεις και χρησεις αυτων
UY32487A (es) Composiciones farmacéuticas de liberación inmediata comprendiendo oxicodona y naloxona
CY1112376T1 (el) Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2
CY1108324T1 (el) Νεοι τεταρτοταγοποιημενοι εστερες κουινουκλιδινης
CY1115725T1 (el) Ενωσεις, συνθεσεις και μεθοδοι για την θεραπευτικη αγωγη των βητα-αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων
CY1115556T1 (el) Φαρμακευτικη συνθεση για χορηγηση απο το στομα η οποια περιλαμβανει ετεξιλικη δαβιγατρανη
CY1113726T1 (el) Χρηση της πασιρεοτιδης για την αντιμετωπιση της ενδογενους υπερινσουλιναιμικης υπογλυκαιμιας
UY29639A1 (es) Amidas sustituidas con heteroarilo que comprenden un grupo enlazador insaturado o cíclico, y su uso como productos farmacéuticos
TR201821157T4 (tr) İbandroni̇k asi̇t veya bunun farmasöti̇k olarak kabul edi̇lebi̇li̇r bi̇r tuzu ve d vi̇tami̇ni̇ i̇çeren oral uygulamaya yöneli̇k kati bi̇leşi̇m.
CY1112227T1 (el) Πιπεριδινυλαμινο-πυριδαζινες και η χρηση τους ως ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2